And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Eczema

DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates thumbnail
Play Button

DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates

Series: DermWire TV | July 30, 2020

The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of Dermatology's Climate Change Committee. FDA has approved MC2 Therapeutics Wynzora Cream for once-daily topical treatment of plaque psoriasis in adults. Tremfya is the first IL-23 inhibitor FDA-approved for active psoriatic arthritis. AbbVie's upadacitinib met both primary and all secondary endpoints in Measure Up 2, the second Phase 3 study in individuals with moderate to severe atopic dermatitis.

Watch Video
Updates on AD Therapeutics thumbnail
Play Button

Updates on AD Therapeutics

Series: Dermatology Dispatches | April 2, 2020

It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And there are biologics—IL-13 and IL-31 inhibitors—and JAK inhibitors in the pipeline showing promise.

Watch Video
Advances in Treating Pediatric Inflammatory Skin Diseases thumbnail
Play Button

Advances in Treating Pediatric Inflammatory Skin Diseases

Series: Maui Derm for Dermatologists 2020 | February 12, 2020

From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis. 

Watch Video
Updates in Pediatric Dermatology thumbnail
Play Button

Updates in Pediatric Dermatology

Series: Maui Derm for Dermatologists 2020 | January 27, 2020

2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.

Watch Video
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates thumbnail
Play Button

DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates

Series: DermWire TV | January 21, 2020

On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.

Watch Video

Advertisement

The Latest in Eczema

Advertisement

View more